Gotistobart vs Tremelimumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: CTLA-4 · full Non-Small Cell Lung Cancer pipeline

Gotistobart

Developed by OncoC4, Inc.

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT04140526 (registry estimate)

No aligned efficacy figure on record for this race.

Tremelimumab

Marketed by AstraZeneca and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT02453282 · Phase 3 · active, not recruiting

The trial was randomized against an active chemotherapy comparator in 1,118 patients, with hard cancer endpoints, but it had no blinding. For tremelimumab, the durvalumab plus tremelimumab comparison with chemotherapy missed both primary endpoints in the PD-L1-high group (overall survival hazard ratio 0.85, p=0.202; progression-free survival hazard ratio 1.05, p=0.705). A well-designed trial with a negative result is graded moderate.

Next expected readout: December 2026 · NCT05000710 (registry estimate)

Reported efficacy

Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).); Progression-Free Survival (PFS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy (Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).): Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) (missed)

Result source: NCT02453282

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGotistobartTremelimumab
PFS, median—Trial running · NCT056715103.9 vs 5.4vs SoC Chemotherapyn 163NCT02453282
11 other results
OS, median—Trial running · NCT0567151011.9 vs 16.3vs Durvalumabn 163NCT02453282
9 other results
ORR—Trial running · NCT0567151034.4% vs 35.6%vs Durvalumabn 163NCT02453282
4 other results
  • 25.3% vs 33.6% n 296 · Phase 3 · secondary NCT02453282
  • 24.7% vs 22.2% n 372 · Phase 3 · secondary NCT02453282
  • 14.9% vs 6.8% n 174 · Phase 3 · secondary NCT02352948
  • 6.7% vs 6.8% n 60 · Phase 3 · secondary NCT02352948
Duration of response, median—Trial running · NCT056715107.4 vs 6vs D + SoCn 155NCT03164616
6 other results

PFS, median

Gotistobart
—Trial running · NCT05671510
Tremelimumab
3.9 vs 5.4vs SoC Chemotherapyn 163NCT02453282
11 other results

OS, median

Gotistobart
—Trial running · NCT05671510
Tremelimumab
11.9 vs 16.3vs Durvalumabn 163NCT02453282
9 other results

ORR

Gotistobart
—Trial running · NCT05671510
Tremelimumab
34.4% vs 35.6%vs Durvalumabn 163NCT02453282
4 other results
  • 25.3% vs 33.6% n 296 · Phase 3 · secondary NCT02453282
  • 24.7% vs 22.2% n 372 · Phase 3 · secondary NCT02453282
  • 14.9% vs 6.8% n 174 · Phase 3 · secondary NCT02352948
  • 6.7% vs 6.8% n 60 · Phase 3 · secondary NCT02352948

Duration of response, median

Gotistobart
—Trial running · NCT05671510
Tremelimumab
7.4 vs 6vs D + SoCn 155NCT03164616
6 other results
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Gotistobart: no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Gotistobart: 0 of 4 rows · Tremelimumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricTremelimumab
Dropout rate
76.3%a
NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 5 more results
n/a: no completion milestone
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
74.1%Sub-study B: Durvalumab+Tremelimum
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
81.7%Sub-study B: Tremelimumab
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
78.3%Arm A: BI 1361849 mRNA Vaccine + D
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
91.2%Arm B: BI 1361849 mRNA Vaccine + D
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
Discontinued due to AEs
—a
NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 5 more results
—
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—Sub-study B: Durvalumab+Tremelimum
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—Sub-study B: Tremelimumab
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
4.3%Arm A: BI 1361849 mRNA Vaccine + D
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
11.8%Arm B: BI 1361849 mRNA Vaccine + D
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
Serious AEs
44.2%a
NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 5 more results
48%
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
37.6%Sub-study B: Durvalumab+Tremelimum
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
38.3%Sub-study B: Tremelimumab
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
60.9%Arm A: BI 1361849 mRNA Vaccine + D
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
64.7%Arm B: BI 1361849 mRNA Vaccine + D
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
Most frequent reported AEs
a
anaemia 45.5%
nausea 41.2%
neutropenia 29.7%
NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 5 more results
decreased appetite 24%
fatigue 21.6%
nausea 21%
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
diarrhoea 20.8%
decreased appetite 19.7%
asthenia 17.9%
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
diarrhoea 26.7%
pruritus 23.3%
decreased appetite 20%
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
decreased appetite 34.8%
fatigue 34.8%
anaemia 30.4%
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
cough 35.3%
fatigue 32.4%
nausea 32.4%
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Tremelimumab

PFS 6.2 vs 5.5 D + SoC months
time to event · months
NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 7 more results
3.9 vs 5.4 SoC Chemotherapy months
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
3.9 vs 4.7 Durvalumab months
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
2.8 vs 3.6 Durvalumab months
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
2.9 vs 2.8 Durvalumab months
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
3.5 vs 3.8 Durvalumab months
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
3.5 vs 3.1 Durvalumab months
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
2.1 vs 3.1 Durvalumab months
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Overall Survival 14 vs 13.3 D + SoC months
time to event · months
NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 7 more results
11.9 vs 16.3 Durvalumab months
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
11.9 vs 16.3 Durvalumab months
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
10.9 vs 14.6 Durvalumab months
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
11.2 vs 12.3 Durvalumab months
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
11.5 vs 11.7 Durvalumab months
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
11.5 vs 10 Durvalumab months
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
6.9 vs 10 Durvalumab months
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
ORR 46.3% (n=335) vs 48.5% (n=330) D + SoC
absolute value · percentage points
NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Duration of Response 7.4 vs 6 D + SoC months
time to event · months
NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 5 more results
NA vs NA Durvalumab months
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
NA vs NA Durvalumab months
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
NA vs NA Durvalumab months
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
12.2 vs 9.5 Durvalumab months
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
4.7 vs 9.5 Durvalumab months
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
PFS2 10.4 vs 10.2 D + SoC months
time to event · months
NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 5 more results
10.9 vs 12.7 Durvalumab months
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
9.4 vs 10.6 Durvalumab months
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
9.8 vs 9.3 Durvalumab months
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
9.1 vs 6.7 SoC months
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
5.7 vs 6.7 SoC months
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
ORR 34.4% (n=163) vs 35.6% (n=163) Durvalumab
responder rate · % of participants
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 4 more results
25.3% (n=296) vs 26.5% (n=279) Durvalumab
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
24.7% (n=372) vs 22.2% (n=374) Durvalumab
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
14.9% (n=174) vs 35.5% (n=62) Durvalumab
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
6.7% (n=60) vs 35.5% (n=62) Durvalumab
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
APF12 25.8% (n=163) vs 32.3% (n=163) Durvalumab @ 52wk
responder rate · % of participants
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 4 more results
20.4% (n=296) vs 27% (n=279) Durvalumab @ 52wk
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
19.8% (n=372) vs 22.5% (n=374) Durvalumab @ 52wk
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
20.6% (n=174) vs 19.4% (n=62) Durvalumab @ 48wk
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
7.3% (n=60) vs 19.4% (n=62) Durvalumab @ 48wk
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
EORTC QLQ-C30 Fatigue -1.1 vs 1.2 Durvalumab score @ 52wk
absolute change · score
EORTC QLQ-C30: Fatigue
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
EORTC QLQ-C30 Appetite Loss 2.4 vs -3.9 Durvalumab score @ 52wk
absolute change · score
EORTC QLQ-C30: Appetite loss
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
EORTC QLQ LC13 Cough -5.9 vs -11.4 Durvalumab score @ 52wk
absolute change · score
EORTC QLQ-LC13: Cough
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
EORTC QLQ-LC13 Chest Pain 1.6 vs 0.1 Durvalumab score @ 52wk
absolute change · score
EORTC QLQ-LC13: Chest pain
NCT02453282 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
OS Rate at 12 49.5% (n=174) vs 49.3% (n=62) Durvalumab @ 48wk
responder rate · % of participants
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
41.2% (n=60) vs 49.3% (n=62) Durvalumab @ 48wk
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3

+ 7 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Gotistobart's landscape · Tremelimumab's landscape